VXi has recruited an outstanding Board of Directors. Dr. Vesely and Mr. Blankenship have board seats, with Mr. Blankenship being the Chairman. Other Board members are:

John Parrish, President and Chief Executive Officer of BioVascular, Inc.

Mr. Parrish is a founder, Director, President and Chief Executive Officer of BioVascular, Inc. He has founded and been founding CEO of two medical device and four pharmaceutical companies, and has over 30 years of medical industry experience. He was previously President/CEO of Angiosyn, Inc. (acquired by Pfizer), Optobionics Corp. (privately held), Valley Forge Pharmaceuticals (privately held), ISTA Pharmaceuticals (publicly held), Intramed Labs. (publicly held), and Vitalmetrics, Inc. (publicly held). Previously he had served IVAC Corp. and Baxter Healthcare in various management positions. He is a member of the Board of Directors of CardioOptics Corp., Valley Forge Pharmaceuticals, and the Discovery Eye Foundation at University of California, Irvine. He holds a B.S. degree in Biology/Chemistry from Wake Forest University, where he served on the schools Board of Visitors. TOP

Harold Wodlinger, Ph.D., Chairman of the Board for Z-Tech Inc.

Harold Wodlinger is Chairman of the Board of Z-Tech Inc., a breast cancer detection company, and a Director of VisualSonics Inc., a pre-clinical imaging company, and SciSense Inc., a company that manufactures cardiac catheters for pre-clinical research. He is a member of the Scientific Advisory Board of the Vengrowth Capital Lifesciences Fund and of the Strategic Program Selection Committee of the Natural Sciences and Engineering Research Council of Canada. Dr. Wodlinger acts as a consultant to the Medical Device industry, and in that capacity performs due diligence on behalf of venture capital investors, and performs strategic planning, engineering management, design auditing, and business development on behalf of medical device companies. TOP

James A. Bowman, CEO of Tissue Genetics Inc.

James Bowman has spent 25 years in the medical device industry in various director and management positions with both large and emerging companies. Jim is currently the Chief Executive Officer of Tissue Genetics Inc., a predictive medicine company with patented technology for diagnosing genetic diseases. Tissue Genetics is launching unique, disruptive technology that will create a new paradigm in identifying and treating hereditary diseases. Jim is the former President & CEO of Encision Inc., a medical device company focused on advancing safety and efficacy in minimally-invasive surgery. Mr. Bowman led this start-up to 300% revenue increases, profitability, positive cash flow and wide industry endorsements. In his 4 years as CEO and Director, Mr. Bowman led Encision to a 500% market cap increase and the listing of its securities on the American Stock Exchange. Jim has a degree in Bio-Medical Engineering with Marquette University and is an alumnus of the Harvard Business School. He is an active member and participant in the Health Industry Alumni Association at Harvard Business School. TOP